| Acronym | Study Title | Ethics Reference | Principle Investigator |
Trial Co-ordinator |
Study Status |
|---|---|---|---|---|---|
| ACUTE LYMPHOBLASTIC LEUKAEMIA | |||||
|
(Dasatinib for Ph+ ALL) |
A PHASE II STUDY OF DASATINIB COMBINED WITH INDUCTION CHEMOTHERAPY IN PREVIOUSLY UNTREATED DE NOVO PHILADELPHIA + ACUTE LYMPHOBLASTIC LEUKAEMIA | Dr Andrew Butler | Jo Sanders | open to accrual | |
| ACUTE MYELOID LEUKAEMIA | |||||
|
|
AML17 IS A RANDOMISED, CONTROLLED, OPEN LABEL PHASE III TRIAL FOR PATIENTS WITH AML AND HIGH RISK MYELODYSPLASTIC SYNDROME (MDS) | MEC/09/11/120 | Dr Ruth Spearing | Jo Sanders | open to accrual |
|
|
allo stem cell transplantation with reduced conditioning
(RICT) versus best standard of care in AML in first complete remission. PROTOCOL NUMBER: TRALG1/02 |
URB/ 06/06/043 |
Dr Ruth Spearing | Jo Sanders | open to accrual |
| CHRONIC LYMPHOCYTIC LEUKAEMIA | |||||
|
(Lenalidomide for CLL maintenance) |
A PHASE 3, MULTICENTRE RANDOMISED, DOUBLE-BLIND,
PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF
LENALIDOMIDE (REVLIMID) AS MAINTENANCE THERAPY FOR PATIENTS WITH B-CELL
CLL FOLLOWING SECOND-LINE THERAPY. PROTOCOL NUMBER: CC-5013-CLL-002 |
Dr Steve Gibbons | Jo Sanders | open to accrual | |
|
|
A RANDOMIZED, OPEN-LABEL MULTICENTRE, PHASE2/3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LUMILIXIMAB IN COMBINATION WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB ALONE IN SUBJECTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA. | Dr Peter Ganly | Jo Sanders | open to accrual | |
|
|
A PHASE 3, MULTICENTRE, RANDOMIZED, OPEN-LABEL,
PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID)
VERSUS CHLORAMBUCIL AS FIRST LINE THERAPY FOR PREVIOUSLY UNTREATED
ELDERLY PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA. PROTOCOL NO. CC-5013-CLL-008 |
Dr Steve Gibbons | Jo Sanders | open to accrual | |
|
|
AN OPEN-LABEL, MULTI-CENTRE, THREE ARM RANDOMISED, PHASE
III STUDY TO COMPARE THE EFFICACY AND SAFETY OF RO5072759 + CHLORAMBUCIL
(GClb), RITUXIMAB + CHLORAMBUCIL (RClb) OR CHLORAMBUCIL (Clb) ALONE IN
PREVIOUSLY UNTREATED CLL PATIENTS NOT ELIGIBLE FOR FLUDARABINE-BASED
CHEMOIMMUNOTHERAPY. PROTOCOL NO:CLL11 (B021004D) |
Dr Andrew Butler | Jo Sanders | open to accrual | |
| CHRONIC MYELOID LEUKAEMIA NO CURRENT TRIALS | |||||
| IDIOPATHIC THROMBOCYTOPENIC PURPURA | |||||
|
|
A MULTI-CENTRE, SINGLE ARM, PHASE II STUDY TO EVALUATE THE EFFICACY OF A WEEKLY 100MG DOSE OF RITUXIMAB OVER FOUR WEEKS IN PATIENTS WITH REFRACTORY OR RELAPSING IDIOPATHIC THROMBOCYTOPENIC PURPURA (THE R-100 ITP STUDY) | MEC/09/02/018 | Dr Ruth Spearing | Jo Sanders | open to accrual |
| MULTIPLE MYELOMA NO CURRENT TRIALS | |||||
|
(Indolent NHL) |
AN OPEN-LABEL, RANDOMIZED, PARALLEL-GROUP STUDY OF
BENDAMUSTINE HYDROCHLORIDE AND RITUXIMAB (BR) COMPARED WITH RITUXIMAB,
CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISONE (R-CVP) OR RITUXIMAB,
CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (R-CHOP) IN
THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED INDOLENT
NON-HODGKIN'S LYMPHOMA (NHL) OR MANTLE CELL LYMPHOMA (MCL). PROTOCOL NUMBER: C18083/3064/NL/MN |
Dr Peter Ganly |
Jo Sanders | open to accrual | |
|
|
A TWO-STAGE PHASE III, INTERNATIONAL , MULTI-CENTRE,
RANDOMISED, CONTROLLED, OPEN-LABEL STUDY TO INVESTIGATE THE
PHARMACOKINETICS, EFFICACY AND SAFETY OF RITUXIMAB SC IN COMBINATION
WITH CHOP OR CVP VERSUS RITUXIMAB IV IN COMBINATION WITH CHOP OR CVP IN
PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA FOLLOWED BY
MAINTENANCE TREATMENT WITH EITHER RITUXIMAB SC OR RITUXIMAB IV. PROTOCOL NUMBER: B022334/A |
MEC/10/09/098 | Dr Andrew Butler | Helen McDermott | open to accrual |
| PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA | |||||
|
|
OBSERVATIONAL REGISTRY COMPILING DATA ON THE HISTORY AND MANAGEMENT OF PATIENTS DIAGNOSED WITH PNH |
URA/ 06/02/001 |
Dr Ruth Spearing | Jo Sanders | open to accrual |
| PRIMARY THROMBOCYTHAEMIA | |||||
|
|
A RANDOMISED TRIAL TO COMPARE ASPIRIN VERSUS HYDROXYUREA/ASPIRIN
IN 'INTERMEDIATE RISK' PT AND ASPIRIN ONLY WITH OBSERVATION IN 'LOW
RISK' PT PROTOCOL NUMBER: PT1 |
00/11/157 | Dr Steve Gibbons | Jo Sanders | open to accrual |
| SUPPORTIVE CARE | |||||
|
|
PHARMACOKINETICS AND SAFETY OF SOLID ORAL POSACONAZOLE
(SCH56592) IN SUBJECTS AT HIGH RISK FOR INVASIVE FUNGAL INFECTIONS
(PHASE 1B) PROTOCOL No. P05615 |
Dr Liam Fernyhough | Jo Sanders | open to accrual | |
|
|
A MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND,
PLACEBO-CONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH
MYELODYSPLASTIC SYNDROMES (LOW/INT-1 RISK) AND TRANSFUSIONAL IRON
OVERLOAD (TELESTO) PROTOCOL NUMBER: CICL670A2302 |
Dr Ruth Spearing | Jo Sanders | open to accrual | |
| TRANSPLANT | |||||
|
(Post Allo SCT) |
A TREATMENT ALGORITHM EVALUATING THE EFFECT OF ZOLEDRONIC ACID ON BONE MINERAL DENSITY LOSS AFTER ALLOGENIC STEM CELL TRANSPLANTATION. | MEC/09/02/010 | Dr Peter Ganly | Jo Sanders | open to accrual |